Hereditary and rare nephropathies

ORIGINAL ARTICLE

Understanding the physical and emotional impact of early-stage ADPKD: experiences and perspectives of patients and physicians

Anna Baker¹, Dominic King², James Marsh³, Andrew Makin⁴, Alison Carr⁵, Catherine Davis⁵, and Cara Kirby⁵

¹London Metropolitan University, London, UK, ²Imperial College, University of London, London, UK, ³St Helier Hospital, Carshalton, UK, ⁴Otsuka Europe Development and Commercialisation, Buckinghamshire, UK, and ⁵Hamell, London, UK

Correspondence to: Alison Carr; E-mail: alison@hamell.co.uk

Abstract

Background: Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary renal disorder; however, at the time this research was conducted, no disease-modifying treatment was currently available. Medical texts often describe early-stage disease (Stages 1 and 2) as asymptomatic, but there is evidence from patients of considerable physical and emotional effects.

Methods: In-depth interviews were conducted with 80 ADPKD patients, 72 nephrologists and 85 primary care physicians (PCPs) from nine European countries to explore the experience and impact of early-stage ADPKD. Interviews were transcribed, translated and analysed centrally using thematic analysis. An additional 600 physicians completed standardised online questionnaires to investigate perceptions of symptom severity and management of early-stage ADPKD.

Results: Eighty-eight per cent of patients with early-stage disease reported physical symptoms including pain, fatigue, breathlessness, weakness and a general malaise. However, 24% of nephrologists and 16% of PCPs perceived that the patients with early-stage disease did not experience any physical symptoms at all. There was a greater awareness of the emotional impact of disease, but this was still underestimated when compared with patient-reported experiences, which highlighted widespread feelings of loss, uncertainty and fear.

Patients and physicians experienced frustration due to the lack of treatment options, especially in the long latent period. For many patients, the inability to affect their disease course whilst living with a diagnosis resulted in feelings of hopelessness, helplessness and depression. Physicians identified a need for improved cooperation between health-care professionals, and increased psychological support for patients.

Conclusions: Early-stage ADPKD can have a significant physical and emotional impact on patients. Whilst some physicians have an awareness of patient experience during early-stage disease, most underestimate the impact of ADPKD. Both patients and physicians are negatively affected by their inability to alter disease progression.

Received: October 15, 2014. Accepted: June 23, 2015

© The Author 2015. Published by Oxford University Press on behalf of ERA-EDTA.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
**Introduction**

Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited renal disorder, affecting less than 5 in 10,000 people [1]. The disease is characterised by the development and progression of renal cysts, leading to increased kidney volume, reduced renal function and eventual progression to end-stage renal disease (ESRD) [2-4]. Initial clinical manifestations include haematuria, hypertension, pain, fatigue and gastrointestinal symptoms [3, 5].

In contrast to the severity of these latter stages, the early phase of ADPKD is often described as being asymptomatic, until the third or fourth decade of life when renal function begins to decline [6, 7]. No effective disease-modifying drugs are currently available to treat ADPKD; clinical management of early disease generally consists of hypertension control and disease monitoring [8, 9]. Limited research examining the initial phase of ADPKD prior to the development of chronic kidney disease (CKD) has been published; however, there is growing evidence to suggest that patients can suffer symptoms, such as pain and fatigue, during the early stage of their disease [10, 11]. Back pain is the most common factor leading to ADPKD diagnosis, often experienced by patients in early disease with normal renal function [10-13].

In addition to these physical symptoms, a diagnosis of ADPKD may have considerable psychological effects. In line with the other diseases that can be diagnosed years before the onset of pathognomonic symptoms, but for which no early treatment can be offered, the burden of knowledge of future disease may have negative psychological implications [14]. Even in those experiencing the classically described asymptomatic latent phase, the psychological impact of living with the disease remains [6]. Patients may live for many years with the knowledge of their diagnosis, aware that their disease is progressing but unable to take any action to ameliorate this process. Furthermore, due to its heritable nature, many patients will have witnessed the effects of ADPKD in close relatives and are conscious of the future that awaits them. These patients are, therefore, ‘faced with an entity that affects their psychological and emotional state as well as their physical condition’ [15]. Reductions in quality of life (QoL) and an increased rate of anxiety and depression are well described in CKD and ESRD patients, including those with late-stage ADPKD [15-17]. However, this research was directed towards the later stages of disease, and studies investigating the psychological well-being of pre-diagnosis ADPKD patients are limited and inconclusive.

This study was undertaken to explore patient and physician experiences and perceptions of early-stage ADPKD.

**Materials and methods**

This cross-sectional study was designed to determine the experience and impact of ADPKD on patients in early-stage disease (CKD Stages 1 and 2) and to elicit the perceptions and beliefs of primary care physicians (PCPs) and nephrologists. All participants gave informed consent. Ethical approval was obtained from Reading Independent Ethics Committee (reference: 280613-1).

**Subjects**

**Patients**

A total of 80 patients over 18 years of age with a diagnosis of ADPKD were recruited through patient organisations and advertisements in clinical centres. Patients were recruited from the following countries: 10 patients each from the UK, Germany, France, Italy and Spain (EU5 countries); 10 from both Finland and Denmark; and 5 from both Sweden and Norway.

Purposive recruitment was used to ensure that the distribution of patients in the sample group reflected all CKD stages of disease. Eleven per cent of patients had Stage 1 disease, 20% Stage 2, 19% Stage 3, 23% Stage 4 and 27% Stage 5. The mean age of participating patients was 50 years (SD 12.46, min–max 20–74 years), and 62% were female. Patients with early-stage disease provided information about their current level of symptoms and disease impact; those in later stages provided retrospective comments.

**Physicians**

From the same nine countries, 757 physicians were recruited from online communities and panels of doctors expressing a willingness to participate in the research. Of these, 157 participated in interviews, of which 72 were nephrologists and 85 were PCPs. A further 300 nephrologists and 300 PCPs completed online questionnaires. The number sampled from each country reflected the distribution of PCPs and nephrologists across Europe.

Eligible physicians were over 25, qualified and practising within their specialty for over 1 year, with at least 50% of their time in direct patient care. Nephrologists managed three or more ADPKD patients per month, and PCPs at least two patients every 6 months.

**Data collection and analysis**

Subjects took part in one-to-one semi-structured telephone interviews of ~1 h conducted by trained qualitative interviewers. Interview questions were designed by clinical experts and qualitative researchers to allow a full exploration of the areas of interest. Patient topics included their disease and treatment pathway; understanding of and reaction to their diagnosis; and experiences, understanding, perceptions, beliefs and expectations of ADPKD and its treatment. Physician topics included assessment of severity and stage of ADPKD; perceptions of the impact of early disease on patients; and their awareness, experience and role in the management of early-stage disease. All interviews were recorded, transcribed and translated into English. Using a phenomenological approach, each transcript was thematically analysed by two qualitative researchers. Commenting and coding were performed to allow interpretation as well as categorisation of the data. Codes were compared and, in cases of disagreement, codes were agreed following discussion. Analysts worked together to develop and agree themes.

Interview responses were used to construct standardised questionnaires capturing physician perceptions of the impact of early-stage ADPKD. A further 600 participants completed these online, and descriptive statistics were used to analyse data from the quantitative questionnaire data using SPSS v19.

**Results**

**Current experiences of patients with early-stage disease**

**Physical symptoms in early-stage ADPKD**

Considerable physical symptoms of early-stage disease were reported in this study by patients with early-stage disease. Of the 25 patients currently with CKD Stage 1 or 2, 22 (88%) reported...
symptoms including back, abdominal or kidney pain, fatigue, breathlessness, weakness and general malaise (Table 1). In most patients, these symptoms were severe enough to inhibit work and physical activity/exercise.

Theme 1: Pain and discomfort. Patients in early-stage disease described both intermittent pain—with acute episodes of severe pain (for example, when a cyst ruptured)—and more prolonged episodes of poorly defined backache or a feeling of abdominal heaviness. Discomfort or breathlessness caused by abdominal bloating and a feeling of pressure was commonly reported. For some patients, discomfort was related to repeated urinary tract infections or digestive problems.

Theme 2: Fatigue and weakness. Although fatigue and weakness were more severe and more frequently reported in later-stage disease, some patients were significantly inhibited by these symptoms pre-diagnosis, or in early disease.

Emotional impact of diagnosis
During early-stage disease, the psychological impact of ADPKD was widespread and represented by the three main themes described below. For many patients, the emotional impact of the diagnosis was devastating, either because they had witnessed the effects of ADPKD in a close relative, or in sporadic cases due to the unexpected nature of the diagnosis (Table 2).

Table 1. Patient experiences of physical symptoms in early-stage ADPKD

- Tiredness and fatigue
- Pain and discomfort

Illustrative quotes from patients with early-stage ADPKD:
'The word “fatal” was used a lot.' [UK 053]
'It’s a bit unsure when you don’t know how fast this disease will advance. You are always thinking when will it be the stage where dialysis is needed.' [FI 001]
'Afraid of the future. There are people who think that something bad could or couldn’t happen. I already know that something bad will happen for sure.' [FI 900]
'Honestly I am scared now. As much as I did not care before, now I am scared.' [FR 311]

Table 2. Patient experience of ADPKD diagnosis and latent period

ADPKD diagnosis
- Loss
- Uncertainty
- Fear

Latent period
- Long latent period with no treatment and little contact with health-care professionals
- Hopelessness and helplessness
- Distress and frustration
- Coping strategies

Illustrative quotes:
Diagnosis:
'The word “fatal” was used a lot.' [UK 053]
'It’s a bit unsure when you don’t know how fast this disease will advance. You are always thinking when will it be the stage where dialysis is needed.' [FI 001]

Latent period:
'In my case they couldn’t do so much—it took 20 years before we began with the treatments.' [FN 10101]
'It took about 12–13 years. The kidneys functioned quite well. I went for frequent follow-ups so as long as they function well you do not do anything. At least not at that point.' [SWE 10008]
'I wish I hadn’t known about it because it was like living with a ticking time bomb.' [UK 098]
'I am just waiting for when it will get worse. It is just waiting.' [FI 001]
'When it comes to treatment they have not told me much, because they do not know much themselves.' [NOR 10203]
'I maintain my weight, I don’t drink excessively, I don’t smoke, I try and have a low salt diet, I try and have a healthy diet. . . . . I think all of those things are worth doing.' [UK 187]
'Then I mainly tried to forget about the disease.' [FI 001]
ADPKD during the latent phase, when the diagnosis has been made but treatment is not available (Table 2). All patients were included in the analysis for Theme 1, to allow representation of the entire latent period. Only interviews from patients in the early stages were examined for Themes 2–4.

Theme 1: Management during early stages. Some patients described latent periods of up to 40 years. Management during this phase included regular but infrequent visits to their physician, with some patients reporting intervals of over a year. Blood pressure monitoring and management of hypertension were the main intervention during this phase.

Theme 2: Hopelessness/helplessness. Fifty-six per cent of early-stage patients reported feelings of hopelessness and helplessness during the latent period. Patients described inevitable disease progression, with their condition advancing towards an unavoidable end point with no possibility of improvement or cure. This inability to influence their disease often led to frustration, with some expressing feelings of anxiety and depression.

Theme 3: Distress and frustration associated with their care. Some patients experienced considerable distress and frustration associated with their care during the latent period. This often resulted from the fact that their physicians were unable to offer disease-modifying treatment. Many patients found the information supplied by their health-care professionals inadequate and some reported that physicians lacked sufficient knowledge relating to ADPKD. For some patients, this was compounded by physicians underestimating the severity of their symptoms.

Theme 4: Coping strategies for the latent period. Despite the negative impact of ADPKD diagnosis on the majority of patients, some reported coping strategies to aid them in the pre-symptomatic stage. These generally fell into one of two categories: lifestyle modification, to improve overall health; or denial—several patients described trying to forget about their diagnosis, or that they considered their disease as something imaginary and they should ‘get on with my life’.

Physician perceptions and experiences

Perception of the patient experience

The frequency of physical effects reported by patients was not reflected in physician perceptions of the disease. Overall, 24% of nephrologists and 16% of PCPs thought that patients with early-stage ADPKD did not experience any physical symptoms. Sixty-seven per cent of nephrologists and 65% of PCPs believed that patients experienced only mild physical symptoms, and 78% of nephrologists and 62% of PCPs thought that early-stage ADPKD had no impact on daily activities (Table 3). There was a greater awareness of the emotional impact of early-stage disease amongst physicians, but this was still underestimated when compared with patient self-reported experiences. Overall, 5% of nephrologists and 7% of PCPs believed that early-stage disease has no emotional impact on patients, and 47% of nephrologists and 45% of PCPs thought that the emotional impact was mild (Table 4).

Physician experiences

Several themes were revealed regarding the management of patients with early-stage ADPKD (Table 5).

The majority of physicians viewed their role during early-stage ADPKD as symptom management, and provision of information and psychological support. Many participants stressed the importance of education and information, with some suggesting that this area is neglected. During the latent period, close monitoring and management of blood pressure were considered critical.

Both PCPs and nephrologists reported a strong desire for treatment to offer their patients early in the course of disease. Many considered that increased psychological support during the latent period and increased cooperation between PCPs and nephrologists would be beneficial. Many physicians expressed frustration, the main contributing factors being inevitable disease progression and the lack of treatment options. Some physicians were frustrated by the medical system, desiring earlier specialist referral and access to additional support for patients, for example, from psychologists.

Reflecting the opinion of some patients, many PCPs expressed their lack of knowledge of the disease, which led to discomfort when dealing with ADPKD patients. Additional training courses or educational material on the subject was mentioned. Furthermore, negative language was frequently used by PCPs when referring to ADPKD as a condition, the QoL of patients and the experience of diagnosing the disease.

Discussion

This study assessed the experience, management, perceptions and expectations of ADPKD during diagnosis and the latent phase both in patients and physicians. Despite the accepted description that early disease is largely asymptomatic, patients experience considerable physical symptoms and negative emotional effects during early-stage disease. Physicians particularly underestimate the physical symptoms.

Our findings show that physical symptoms attributed to ADPKD were widely reported by patients with early disease and

| Table 3. Nephrologists’ and PCPs’ perceptions of the severity of physical symptoms experienced by patients during early-stage ADPKD |
|-----------------|---------------|---------------|
|                  | Nephrologists | PCPs          |
| None             | 73 (24.3)     | 48 (16.0)     |
| Mild             | 201 (66.8)    | 196 (65.3)    |
| Moderate         | 26 (8.6)      | 54 (18.0)     |
| Severe           | 1 (0.3)       | 2 (0.7)       |
| Total            | 301 (100)     | 300 (100)     |

Responses from the additional physicians who completed the online questionnaire.

| Table 4. Nephrologists’ and PCPs’ perceptions of the severity of the emotional impact on patients of early-stage ADPKD |
|-----------------|---------------|---------------|
|                  | Nephrologists | PCPs          |
| None             | 15 (5.0)      | 21 (7.0)      |
| Mild             | 141 (46.8)    | 135 (45.2)    |
| Moderate         | 120 (39.9)    | 129 (43.1)    |
| Severe           | 25 (8.3)      | 14 (4.7)      |
| Total            | 301 (100)     | 299 (100)     |

Responses from the additional physicians who completed the online questionnaire.
were often severe enough to inhibit daily activities. In this study, most physicians acknowledged that patients with early-stage disease may experience physical symptoms including pain, but describe these as uncommon. It has previously been suggested that pain is frequently under-reported by ADPKD patients [18] and under-recognised by physicians, leading to inadequate pain management, particularly in the early stages of disease [19, 20]. Our study supports this finding, highlighting a discrepancy between the physical symptoms reported by patients and the perception by physicians that many patients are asymptomatic. To avoid recall bias, this analysis focussed on patients currently experiencing early-stage disease. However, the results were supported by retrospective comments made by patients in later stages.

Physicians seemed more likely to accept the likelihood of physical symptoms in early disease when there was a medical explanation such as a burst cyst, whereas they struggled to attribute pain to ADPKD where there was no explanation that fit their medical model. However, previous research has shown that both renal and extra-renal abnormalities are present in ADPKD far in advance of impaired renal function, with early detection of cysts and increased total kidney volume along with disruption of many other parameters [6, 7, 21]. The early presence of these manifestations provides an explanation for patients’ experience of pain, suggesting that greater attention should be paid to symptoms in the period preceding declining renal function. Physicians were much more aware of the emotional and psychological impacts of early-stage disease, although they probably still underestimate the far-reaching impact it has on patients’ QoL and well-being.

There has been increasing interest in the psychological effects of many medical conditions, including renal disorders such as ADPKD [15]. In general, many authors conclude that psychological disorders such as anxiety and depression are likely to be under-diagnosed, underestimated and certainly under-treated in patients with CKD, including those with ADPKD [10, 17, 22–24]. However, research examining the earlier stages of ADPKD has been limited and shown conflicting results [16, 17, 25]. This study explored the psychological impact of living with ADPKD during the latent period of disease, indicating that ADPKD patients can suffer considerable psychological difficulties as a result of their diagnosis for years prior to the onset of CKD. In general, patients felt that they were waiting for their disease to progress, leading to considerable distress, frustration and associated negative effects such as depression in some.

Taken together, these findings suggest a lengthy period during which some patients are suffering from pain and fatigue, and many patients are experiencing psychological distress, but physicians are unaware of or underestimating their difficulties. These results challenge the currently accepted description of early-stage disease as asymptomatic and suggest that increased access to pain management and psychological support would likely improve management within the current framework of care.

This study is the first to assess the impact of the latent period on physicians as well as patients. Both PCPs and nephrologists expressed frustration at the lack of disease-modifying treatments available (at the time this research was conducted) and their subsequent inability to hinder disease progression. Some PCPs felt uncomfortable with their lack of knowledge and inexperience in dealing with ADPKD, mirroring the feelings expressed in patient interviews. In contrast, nephrologists generally appeared confident in these areas, despite some patients expressing dissatisfaction regarding these aspects of their specialist care. Physicians from both the groups felt that increased psychological support for patients in the early stages of the disease may be beneficial.

The use of qualitative analysis relies on smaller sample sizes than quantitative studies. Analysis of the large amounts of
interview data produced is a subjective process; however, this is performed by trained researchers using well-established methods to interpret the wealth of information produced. Qualitative methodologies offer the opportunity to allow in-depth exploration and insight into experiences, attitudes and beliefs. As such, objective measures of a single aspect of disease (such as pain) would result in a narrower picture of ADPKD, and a qualitative, interview-based approach was considered appropriate for this study. This research advances the understanding of the impact of ADPKD on patients and physicians across nine European countries. Further research would be useful to explore cultural differences in patient experience and physician perceptions.

In conclusion, this study demonstrates the negative physical and emotional effects of ADPKD from the time of diagnosis throughout the latent period. Whilst some physicians have an accurate awareness of patient experience during early-stage disease, most underestimate the impact of ADPKD. These results highlight the frustration experienced by patients and physicians at their inability to affect disease outcome. Nonetheless, in the absence of active treatment options, suggestions can be made to improve patient and physician experiences of this disease.

Acknowledgements

The authors would like to thank all patients and physicians who took part in this study, as well as the patient organisations in the participating countries and the international ADPKD patient organisation. The authors acknowledge Katerina Kelesidi from Hamell for providing support with the data analysis and Jennifer Brewin for medical writing.

Conflicts of interest statement

A.M. is an employee of Otsuka. The research was sponsored by Otsuka. Hamell was paid by Otsuka to design and implement the research and to analyse the data. Otsuka had no access to the raw data, and the analysis was conducted completely independently by Hamell.

The results presented in this paper have not been presented previously in whole or part except in abstract form.

Authors’ contributions

A.C. designed and performed the research and wrote and reviewed the paper. C.D. and C.K. performed the research and reviewed the paper. A.M. was involved in the study design and reviewed the paper. J.M. was involved in the study design, reviewed the data and wrote and reviewed the paper. D.K. and A.B. reviewed the data and contributed to and reviewed the paper. Hamell undertook the analysis.

Funding

This research was funded by Otsuka Europe.

References

1. Neumann H, Jilg C, Bacher J, Nabulsi Z, Malinoc A et al. Epidemiology of autosomal-dominant polycystic kidney disease: an in-depth clinical study for south-western Germany. Nephrol Dial Transplant 2013; 28: 1472–1487.

2. Masoumi A, Reed-Gitomer B, Kelleher C et al. Developments in the management of autosomal dominant polycystic kidney disease. Ther Clin Risk Manag 2008; 4: 393–407.

3. Cadnapaphornchai MA, George DM, Masoumi A et al. Effect of statin therapy on disease progression in pediatric ADPKD: design and baseline characteristics of participants. Contemp Clin Trials 2011; 32: 437–445.

4. Chapman AB. Approaches to testing new treatments in autosomal dominant polycystic kidney disease: insights from the CRISP and HALT-PKD studies. Clin J Am Soc Nephrol 2008; 3: 1197–1204.

5. Badani KK, Hemal AK, Menon M. Autosomal dominant polycystic kidney disease and pain—a review of the disease from aetiology, evaluation, past surgical treatment options to current practice. J Postgrad Med 2004; 50: 222–226.

6. Rizk D, Chapman A. Treatment of autosomal dominant polycystic kidney disease (ADPKD): the new horizon for children with ADPKD. Pediatr Nephrol 2008; 23: 1029–1036.

7. Thong KM, Ong AC. The natural history of autosomal dominant polycystic kidney disease: 30-year experience from a single centre. QJM 2013; 106: 639–646.

8. Schrier RW. Optimal care of autosomal dominant polycystic kidney disease patients. Nephrology 2006; 11: 124–130.

9. Grantham JJ. Clinical practice. Autosomal dominant polycystic kidney disease. N Engl J Med 2008; 359: 1477–1485.

10. Miskulin DC, Abebe KZ, Chapman AB et al. Health-related quality of life in patients with autosomal dominant polycystic kidney disease and CKD stages 1–4: a cross-sectional study. Am J Kidney Dis 2014; 63: 214–226.

11. Baiwa ZH, Sial KA, Malik AB et al. Pain patterns in patients with polycystic kidney disease. Kidney Int 2004; 66: 1561–1569.

12. Eloi SR, Nishiura JL, Heilberg IP. Translation, cultural adaptation and application of a pain questionnaire for patients with polycystic kidney disease. Jornal Brasileiro de Nefrologia 2010; 32: 386–399.

13. Nishiura JL, Eloi SR, Heilberg IP. Pain determinants of pain in autosomal dominant polycystic kidney disease. Jornal Brasileiro de Nefrologia 2013; 35: 242–243.

14. Hagberg A, Bui TH, Winnberg E. More appreciation of life or regretting the test? Experiences of living as a mutation carrier of Huntington’s disease. J Genet Couns 2011; 20: 70–79.

15. Perez Dominguez TS, Rodriguez Perez A, Buset Rios N et al. Psychonephrology: psychological aspects in autosomal dominant polycystic kidney disease. Nefrologia 2011; 31: 716–722.

16. Suwabe T, Ubara Y, Mise K et al. Quality of life of patients with ADPKD-Toranomon PKD QOL study: cross-sectional study. BMC Nephrol 2013; 14: 179.

17. de Barros BP, Nishiura JL, Heilberg IP et al. Anxiety, depression, and quality of life in patients with familial glomerulonephritis or autosomal dominant polycystic kidney disease. Jornal Brasileiro de Nefrologia 2011; 33: 120–128.

18. Heiwe S, Bjuke M. “An evil heritage”: interview study of pain and autosomal dominant polycystic kidney disease. Pain Manage Nurs 2009; 10: 134–141.

19. Hogan MC, Norby SM. Evaluation and management of pain in autosomal dominant polycystic kidney disease. Adv Chronic Kidney Dis 2010; 17: e1–e16.

20. Helal I. Autosomal dominant polycystic kidney disease: new insights into treatment. Saudi J Kidney Dis Transpl 2013; 24: 230–234.

21. Meijer E, Rook M, Tent H et al. Early renal abnormalities in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2010; 5: 1091–1098.
22. Abdel-Kader K, Unruh ML, Weisbord SD. Symptom burden, depression, and quality of life in chronic and end-stage kidney disease. Clin J Am Soc Nephrol 2009; 4: 1057–1064.

23. Finkelstein FO, Wuerth D, Finkelstein SH. An approach to addressing depression in patients with chronic kidney disease. Blood Purif 2010; 29: 121–124.

24. Zalai D, Szeifert L, Novak M. Psychological distress and depression in patients with chronic kidney disease. Semin Dial 2012; 25: 428–438.

25. Rizk D, Jurkovitz C, Veledar E et al. Quality of life in autosomal dominant polycystic kidney disease patients not yet on dialysis. Clin J Am Soc Nephrol 2009; 4: 560–566.